Valentina Kutyifa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2402247/publications.pdf

Version: 2024-02-01

203 papers	4,490 citations	117625 34 h-index	138484 58 g-index
205 all docs	205 docs citations	205 times ranked	5090 citing authors

#	Article	IF	Citations
1	Use of oral contraceptives in women with congenital long QT syndrome. Heart Rhythm, 2022, 19, 41-48.	0.7	7
2	Arrhythmic and Mortality Outcomes Among Ischemic Versus Nonischemic Cardiomyopathy Patients Receiving Primary ICD Therapy. JACC: Clinical Electrophysiology, 2022, 8, 1-11.	3.2	12
3	Introducing the all-new Fellows Corner of Heart Rhythm O: The future is here now. Heart Rhythm O2, 2022, 3, 117-118.	1.7	0
4	Primary results from the Japanese Heart Failure and Sudden Cardiac Death Prevention Trial (HINODE). ESC Heart Failure, 2022, 9, 1584-1596.	3.1	5
5	Sex Differences in the Risk of First and Recurrent Ventricular Tachyarrhythmias Among Patients Receiving an Implantable Cardioverter-Defibrillator for Primary Prevention. JAMA Network Open, 2022, 5, e2217153.	5.9	6
6	Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry. Clinical Research in Cardiology, 2021, 110, 102-113.	3.3	13
7	Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator. Heart Rhythm, 2021, 18, 404-410.	0.7	10
8	Reassessing the role of antitachycardia pacing in fast ventricular arrhythmias in primary prevention implantable cardioverter-defibrillator recipients: Results from MADIT-RIT. Heart Rhythm, 2021, 18, 399-403.	0.7	12
9	Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. European Heart Journal, 2021, 42, 1676-1684.	2.2	61
10	Systolic Blood Pressure and Risk for Ventricular Arrhythmia in Patients With an Implantable Cardioverter Defibrillator. American Journal of Cardiology, 2021, 143, 74-79.	1.6	3
11	Risk factors for ventricular tachyarrhythmic events in patients without left bundle branch block who receive cardiac resynchronization therapy. Annals of Noninvasive Electrocardiology, 2021, 26, e12847.	1.1	1
12	Cardiac resynchronization therapy and ventricular tachyarrhythmia burden. Heart Rhythm, 2021, 18, 762-769.	0.7	14
13	Survival After Implantable Cardioverter-Defibrillator Shocks. Journal of the American College of Cardiology, 2021, 77, 2453-2462.	2.8	20
14	Smoking and the Risk of Stroke in Patients with a Left Ventricular Assist device. ASAIO Journal, 2021, Publish Ahead of Print, 1217-1221.	1.6	0
15	Risk Prediction in Women With Congenital Long QT Syndrome. Journal of the American Heart Association, 2021, 10, e021088.	3.7	7
16	Combining diastolic dysfunction and natriuretic peptides to risk stratify patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 335, 59-65.	1.7	2
17	Rationale and design of the HINODE study: Heart failure indication and sudden cardiac death prevention trial Japan. Journal of Arrhythmia, 2021, 37, 1031-1037.	1.2	1
18	Utility of cardiovascular implantable electronic deviceâ€“derived patient activity to predict clinical outcomes. Heart Rhythm, 2021, 18, 1344-1351.	0.7	3

#	Article	IF	Citations
19	Hospitalization for HeartÂFailure and Subsequent Ventricular Tachyarrhythmias in Patients With LeftÂVentricular Dysfunction. JACC: Clinical Electrophysiology, 2021, 7, 1099-1107.	3.2	0
20	Machine learning-based mortality prediction of patients undergoing cardiac resynchronization therapy: the SEMMELWEIS-CRT score. European Heart Journal, 2020, 41, 1747-1756.	2.2	82
21	Prognostic Usefulness of Systolic Blood Pressure One-Year Following Cardiac Resynchronization Therapy (from MADIT-CRT). American Journal of Cardiology, 2020, 125, 777-782.	1.6	1
22	CHA ₂ DS ₂ â€VASc Score and the Risk of Ventricular Tachyarrhythmic Events and Mortality in MADITâ€CRT. Journal of the American Heart Association, 2020, 9, e014353.	3.7	8
23	Clinical Significance of Early Hospital Readmission in Continuous-Flow Left Ventricular Assist Device Patients. ASAIO Journal, 2020, 66, 760-765.	1.6	5
24	Videos to reduce racial disparities in ICD therapy Via Innovative Designs (VIVID) trial: Rational, design and methodology. American Heart Journal, 2020, 220, 59-67.	2.7	5
25	Premature ventricular complexes: diagnostic and therapeutic considerations in clinical practice. Journal of Interventional Cardiac Electrophysiology, 2020, 57, 5-26.	1.3	36
26	Predictors and outcomes of atrial tachyarrhythmia among patients with implantable defibrillators. Heart Rhythm, 2020, 17, 553-559.	0.7	5
27	Outcome by Sex in Patients With Long QT Syndrome With an Implantable Cardioverter Defibrillator. Journal of the American Heart Association, 2020, 9, e016398.	3.7	4
28	Utility of 6-Minute Walk Test to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure. American Journal of Cardiology, 2020, 132, 79-86.	1.6	1
29	Sustained Ventricular Tachyarrhythmia Termination in a Large Cohort of Women Using Wearable Cardioverter-Defibrillators. JACC: Clinical Electrophysiology, 2020, 6, 1187-1188.	3.2	3
30	Applicability of the MADIT-CRT Response Score for Prediction of Long-Term Clinical and Arrhythmic Events by QRS Morphology. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008499.	4.8	1
31	Lateral left ventricular lead position is superior to posterior position in longâ€term outcome of patients who underwent cardiac resynchronization therapy. ESC Heart Failure, 2020, 7, 3374-3382.	3.1	14
32	Competing risk analysis of ventricular arrhythmia events in heart failure patients with moderately compromised renal dysfunction. Europace, 2020, 22, 1384-1390.	1.7	8
33	Remote monitoring of cardiac implanted electronic devices: legal requirements and ethical principles - ESC Regulatory Affairs Committee/EHRA joint task force report. Europace, 2020, 22, 1742-1758.	1.7	32
34	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace, 2020, 22, 1147-1148.	1.7	62
35	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Journal of Arrhythmia, 2020, 36, 553-607.	1.2	40
36	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Heart Rhythm, 2020, 17, e269-e316.	0.7	15

#	Article	IF	Citations
37	Left Atrial Intramural Hematoma After Radiofrequency Catheter Ablation. JACC: Case Reports, 2020, 2, 227-229.	0.6	3
38	True bipolar or extended bipolar left ventricular pacing is associated with better survival in cardiac resynchronization therapy patients. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 412-417.	1.2	0
39	The role and outcomes of new supraventricular tachycardia among patients with mild heart failure. Journal of Cardiovascular Electrophysiology, 2020, 31, 1099-1104.	1.7	0
40	Cardiac Resynchronization Therapy and Risk of Recurrent Hospitalizations in Patients Without Left Bundle Branch Block. Circulation: Heart Failure, 2020, 13, e006925.	3.9	3
41	Circadian variation and seasonal distribution of implantable defibrillator detected new onset atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 1495-1500.	1.2	4
42	Implantable cardioverter-defibrillator programming after first occurrence of ventricular tachycardia in the Multicenter Automatic Defibrillator Implantation Trialâ€“Reduce Inappropriate Therapy (MADIT-RIT). Heart Rhythm O2, 2020, 1, 77-82.	1.7	4
43	Marital Status and Long-Term Outcomes in Mild Heart Failure Patients With an Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator. American Journal of Cardiology, 2020, 125, 1180-1186.	1.6	0
44	Future research prioritization in cardiac resynchronization therapy. American Heart Journal, 2020, 223, 48-58.	2.7	13
45	Relation between resting heart rate and the risk of ventricular tachyarrhythmias in MADIT-RIT. Europace, 2020, 22, 281-287.	1.7	3
46	An International Multicenter Evaluation of Type 5 Long QT Syndrome. Circulation, 2020, 141, 429-439.	1.6	39
47	Need for pacing in patients who qualify for an implantable cardioverterâ€defibrillator: Clinical implications for the subcutaneous ICD. Annals of Noninvasive Electrocardiology, 2020, 25, e12744.	1.1	8
48	Cardiac Resynchronization Therapy for Chemotherapy-Induced Cardiomyopathyâ€”Reply. JAMA - Journal of the American Medical Association, 2020, 323, 1317.	7.4	0
49	AnaLysIs of Both sex and device specific factoRs on outcomes in pAtients with non-ischemic cardiomyopathy (BIO-LIBRA): Design and clinical protocol. Heart Rhythm O2, 2020, 1, 376-384.	1.7	1
50	Decline in physical activity in the weeks preceding sustained ventricular arrhythmia in women. Heart Rhythm O2, 2020, 1, 283-287.	1.7	4
51	Primary prevention with the implantable cardioverter-defibrillator in high-risk long-QT syndrome patients. Europace, 2019, 21, 339-346.	1.7	22
52	Long-term single-centre large volume experience with transseptal endocardial left ventricular lead implantation. Europace, 2019, 21, 1237-1245.	1.7	11
53	Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. Europace, 2019, 21, 1843-1850.	1.7	5
54	Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy. JAMA - Journal of the American Medical Association, 2019, 322, 1799.	7.4	32

#	Article	IF	Citations
55	Left Ventricular Reverse Remodeling in Cardiac Resynchronization Therapy and Long-TermÂOutcomes. JACC: Clinical Electrophysiology, 2019, 5, 1001-1010.	3.2	16
56	Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved BeyondÂGuidelines for a Defibrillator inÂMADIT-CRT. JACC: Clinical Electrophysiology, 2019, 5, 1172-1181.	3.2	3
57	2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Europace, 2019, 21, 1442-1443.	1.7	59
58	Prognostic Importance of Defibrillatorâ€Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure. Journal of the American Heart Association, 2019, 8, e010346.	3.7	9
59	Effectiveness of singleâ€vs dualâ€coil implantable defibrillator leads: An observational analysis from the SIMPLE study. Journal of Cardiovascular Electrophysiology, 2019, 30, 1078-1085.	1.7	5
60	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). Europace, 2019, 21, 844-845.	1.7	68
61	Wearable cardioverter-defibrillator and ventricular arrhythmias: risk stratification in patients with shorter device useâ€"Authorsâ€™ reply. Europace, 2019, 21, 525-526.	1.7	1
62	Longâ€term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction. European Journal of Heart Failure, 2019, 21, 360-369.	7.1	7
63	Cardiac resynchronization therapy: need to synchronize patients and device longevities with comorbidities. Europace, 2019, 21, 683-685.	1.7	2
64	Current status of interventional cardiac electrophysiology training in ESC member countries: an EHRA Young EP Report. Europace, 2019, 21, 522-524.	1.7	4
65	Machine learningâ€based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy. European Journal of Heart Failure, 2019, 21, 74-85.	7.1	175
66	Implantable Cardioverter Defibrillators and Survival in Continuous-Flow Left Ventricular Assist Device Patients. ASAIO Journal, 2019, 65, 49-53.	1.6	9
67	OUP accepted manuscript. Europace, 2019, 21, 1865-1875.	1.7	6
68	Cardiac Resynchronization Therapy for Heart Failure in Patients Without LeftÂBundle Branch Block. , 2019, , 39-55.		0
69	Cybersecurity for Cardiac Implantable Electronic Devices. Journal of the American College of Cardiology, 2018, 71, 1284-1288.	2.8	64
70	Atrioventricular dromotropathy: evidence for a distinctive entity in heart failure with prolonged PR interval?. Europace, 2018, 20, 1067-1077.	1.7	27
71	Clinical aspects of the three major genetic forms of long <scp>QT</scp> syndrome (<scp>LQT</scp>1,) Tj ETQq1 1 0.784314 rgBT /Ov	1.1	33
72	Usefulness of Electrocardiographic Left Atrial Abnormality to Predict Response to Cardiac Resynchronization Therapy in Patients With Mild Heart Failure and Left Bundle Branch Block (a) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	1.6	7

#	Article	IF	Citations
73	Comparison of Long-Term Survival Benefits With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Versus Without Diabetes Mellitus (from the Multicenter Automatic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Journal of Cardiology, 2018, 121, 1567-1574.	1.6	5
74	Quality of life measured with EuroQol-five dimensions questionnaire predicts long-term mortality, response, and reverse remodelling in cardiac resynchronization therapy patients. Europace, 2018, 20, 1506-1512.	1.7	9
75	Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure. American Journal of Cardiology, 2018, 121, 615-620.	1.6	10
76	Influence of Diabetes Mellitus on Outcomes in Patients After Left Ventricular Assist Device Implantation. Annals of Thoracic Surgery, 2018, 106, 555-560.	1.3	17
77	Right ventricular lead location, right-left ventricular lead interaction, and long-term outcomes in cardiac resynchronization therapy patients. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 185-194.	1.3	3
78	Novel electrocardiographic dyssynchrony criteria improve patient selection for cardiac resynchronization therapy. Europace, 2018, 20, 97-103.	1.7	19
79	Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapyâ€defibrillator patients: a <scp>MADIT</scp>â€<scp>CRT</scp> substudy. Annals of Noninvasive Electrocardiology, 2018, 23, e12491.	1.1	12
80	Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients. JACC: Clinical Electrophysiology, 2018, 4, 1410-1420.	3.2	20
81	Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator. Heart Rhythm, 2018, 15, 1379-1386.	0.7	11
82	In memoriam Dr Arthur J. Moss. Europace, 2018, 20, 1060-1062.	1.7	0
83	Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies. Europace, 2018, 20, f240-f248.	1.7	36
84	Readmission Patterns During Long-Term Follow-Up After Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2018, 122, 1021-1027.	1.6	21
85	Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace, 2018, 20, 1565-1565ao.	1.7	186
86	Baseline adverse electrical remodeling and the risk for ventricular arrhythmia in Cardiac Resynchronization Therapy Recipients (MADIT CRT). Journal of Cardiovascular Electrophysiology, 2018, 29, 1017-1023.	1.7	0
87	Effectiveness of high rate and delayed detection ICD programming by race: A MADITâ€RIT substudy. Journal of Cardiovascular Electrophysiology, 2018, 29, 1418-1424.	1.7	1
88	Oneâ€year followâ€up of the prospective registry of patients using the wearable defibrillator (WEARITâ€II) Tj ETQq0 0 0 rgBT /Overlock	1.2	15
89	Non-response to Cardiac Resynchronization Therapy. Current Heart Failure Reports, 2018, 15, 315-321.	3.3	17
90	Predictors of longâ€term mortality with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block. Clinical Cardiology, 2018, 41, 1358-1366.	1.8	4

#	Article	IF	Citations
91	Arthur Jay Moss MD PhD. European Heart Journal, 2018, 39, 1872-1874.	2.2	0
92	Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death. Europace, 2018, 20, f225-f232.	1.7	13
93	Impact of non-cardiovascular disease burden on thirty-day hospital readmission in heart failure patients. Cardiology Journal, 2018, 25, 691-700.	1.2	4
94	Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial. Europace, 2017, 19, euw193.	1.7	17
95	Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial. Europace, 2017, 19, euw116.	1.7	20
96	Discrepancies in the U.S. and European guidelines involving the implantable cardioverterâ€“defibrillator and cardiac resynchronization therapy: Need for a single shared international publication. Heart Rhythm, 2017, 14, 474-475.	0.7	1
97	Is there a need for an implantable cardioverter defibrillator in patients with left ventricular assist devices? Time for MADIT-VAD!. Expert Review of Medical Devices, 2017, 14, 1-2.	2.8	3
98	Questioning the preference for dual- vs. single-chamber implantable defibrillator in primary prevention implantable cardioverter-defibrillator recipients. Europace, 2017, 19, 1416-1417.	1.7	1
99	Very Wide QRS Complex (â‰¥180 ms) andÂCRT Efficacy â^—. Journal of the American College of Cardiology, 2017, 69, 2037-2038.	2.8	0
100	Multiple Comorbidities and Response to Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2017, 69, 2369-2379.	2.8	37
101	Left ventricular assist devices in patients with renal dysfunction: where are we heading?. Expert Review of Medical Devices, 2017, 14, 413-415.	2.8	2
102	Right ventricular apical versus non-apical implantable cardioverter defibrillator lead: A systematic review and meta-analysis. Journal of Electrocardiology, 2017, 50, 591-597.	0.9	5
103	Predictive value of device-derived activity level for short-term outcomes in MADIT-CRT. Heart Rhythm, 2017, 14, 1081-1086.	0.7	14
104	Gender-specific outcomes of cardiac resynchronisation therapy with or without defibrillator. Heart, 2017, 103, 732-733.	2.9	2
105	Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction. Journal of the American Heart Association, 2017, 6, .	3.7	9
106	Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy. American Heart Journal, 2017, 189, 75-84.	2.7	52
107	Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	35
108	Renal Function Changes Following Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2017, 120, 2213-2220.	1.6	13

#	Article	IF	Citations
109	Reply. Journal of the American College of Cardiology, 2017, 70, 2097-2098.	2.8	1
110	Heart failure severity, inappropriate ICD therapy, and novel ICD programming: a MADITâ€RIT substudy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1405-1411.	1.2	5
111	Effect of Gender on the Risk of Neurologic Events and Subsequent Outcomes in Patients With Left Ventricular Assist Devices. American Journal of Cardiology, 2017, 119, 297-301.	1.6	22
112	Clinical presentation at first heart failure hospitalization does not predict recurrent heart failure admission. ESC Heart Failure, 2017, 4, 520-526.	3.1	3
113	Long-Term Survival of Patients With Left Bundle Branch Block Who Are Hypo-Responders to Cardiac Resynchronization Therapy. American Journal of Cardiology, 2017, 120, 825-830.	1.6	11
114	Multicenter Automatic Defibrillator Implantation Trialâ€“Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol. American Heart Journal, 2017, 189, 158-166.	2.7	31
115	Effect of Significant Weight Change on Inappropriate Implantable Cardioverterâ€Defibrillator Therapy. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 9-16.	1.2	4
116	Sex Differences in Inappropriate ICD Device Therapies: MADITâ€II and MADITâ€CRT. Journal of Cardiovascular Electrophysiology, 2017, 28, 94-102.	1.7	8
117	Impact of CT-apelin and NT-proBNP on identifying non-responders to cardiac resynchronization therapy. Biomarkers, 2017, 22, 279-286.	1.9	5
118	Validation of an automatic diagnosis of strict left bundle branch block criteria using 12-lead electrocardiograms. , 2017, 22, e12398.		8
119	Effect of cardiac resynchronization therapy on the risk of ventricular tachyarrhythmias in patients with chronic kidney disease. , 2017, 22, e12404.		2
120	Device-detected subclinical atrial tachyarrhythmias: definition, implications and managementâ€”an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de EstimulaciÃ³n CardÃaca y ElectrofisiologÃa (SOLEACE). Europace, 2017, 19, 1556-1578.	1.7	186
121	Study of the wearable cardioverter defibrillator in advanced heartâ€failure patients (SWIFT). Journal of Cardiovascular Electrophysiology, 2017, 28, 778-784.	1.7	17
122	Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events. Cardiovascular Diabetology, 2016, 15, 93.	6.8	14
123	Predictors and clinical relevance of ventricular tachyarrhythmias in ambulatory patients with a continuous flow left ventricular assist device. Heart Rhythm, 2016, 13, 1052-1056.	0.7	53
124	Letter to the Editorâ€” Prognostic implication of baseline PR interval in patients undergoing cardiac resynchronization therapy. Heart Rhythm, 2016, 13, 1573.	0.7	0
125	Clinical Implications of Complete Left-Sided Reverse Remodeling With CardiacÂResynchronization Therapy. Journal of the American College of Cardiology, 2016, 68, 1268-1276.	2.8	47
126	Reply to the Editorâ€” Bipolar left ventricular pacing is associated with significant reduction in heart failure or death in CRT-D patients with LBBB. Heart Rhythm, 2016, 13, e327-e328.	0.7	0

#	Article	IF	Citations
127	No Utility of the Wearable Cardioverter-Defibrillator in Patients With Nonischemic Cardiomyopathy?. Journal of the American College of Cardiology, 2016, 67, 2807.	2.8	0
128	The Burden and Morphology of Premature Ventricular Contractions and their Impact on Clinical Outcomes in Patients Receiving Biventricular Pacing in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). , 2016, 21, 41-48.		5
129	Predictors and Risk of Ventricular Tachyarrhythmias or Death in BlackÂandÂWhite Cardiac Patients. JACC: Clinical Electrophysiology, 2016, 2, 448-455.	3.2	17
130	Sustained clinical benefit of cardiac resynchronization therapy in non-LBBB patients with prolonged PR-interval: MADIT-CRT long-term follow-up. Clinical Research in Cardiology, 2016, 105, 944-952.	3.3	41
131	Time Dependence of VentricularÂTachyarrhythmias AfterÂMyocardial Infarction. JACC: Clinical Electrophysiology, 2016, 2, 565-573.	3.2	0
132	Relative Wall Thickness and the Risk for Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction. Journal of the American College of Cardiology, 2016, 67, 303-312.	2.8	46
133	Novel ICD Programming and Inappropriate ICD Therapy in CRT-D Versus ICD Patients. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e001965.	4.8	25
134	Longer right to left ventricular activation delay at cardiac resynchronization therapy implantation is associated with improved clinical outcome in left bundle branch block patients. Europace, 2016, 18, 550-559.	1.7	17
135	Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block. Circulation: Heart Failure, 2016, 9, e002667.	3.9	15
136	Bipolar left ventricular pacing is associated with significant reduction in heart failure or death in CRT-D patients with LBBB. Heart Rhythm, 2016, 13, 1468-1474.	0.7	11
137	Cardiac Resynchronization in Different Age Groups: A MADIT-CRT Long-Term Follow-Up Substudy. Journal of Cardiac Failure, 2016, 22, 143-149.	1.7	9
138	Lessons learned from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Trends in Cardiovascular Medicine, 2016, 26, 137-146.	4.9	7
139	Prior hospital admission predicts thirty-day hospital readmission for heart failure patients. Cardiology Journal, 2016, 23, 155-162.	1.2	15
140	Effectiveness of cardiac resynchronization therapy by the frequency of revascularization procedures in ischemic cardiomyopathy patients. Cardiology Journal, 2016, 23, 437-445.	1.2	3
141	Early intervention and longâ€term outcome with cardiac resynchronization therapy in patients without a history of advanced heart failure symptoms. European Journal of Heart Failure, 2015, 17, 964-970.	7.1	11
142	Reduced risk of lifeâ€threatening ventricular tachyarrhythmias with cardiac resynchronization therapy: relationship to left ventricular ejection fraction. European Journal of Heart Failure, 2015, 17, 971-978.	7.1	23
143	Prognostic Significance of Heart Rate Variability Among Patients Treated With Cardiac Resynchronization Therapy. JACC: Clinical Electrophysiology, 2015, 1, 74-80.	3.2	10
144	Identification of Lowâ€Risk Adult Congenital LQTS Patients. Journal of Cardiovascular Electrophysiology, 2015, 26, 853-858.	1.7	7

#	Article	IF	Citations
145	Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADITâ€CRT) Trial. Journal of Cardiovascular Electrophysiology, 2015, 26, 862-871.	1.7	46
146	Reduction in Inappropriate ICD Therapy in MADITâ€RIT Patients Without History of Atrial Tachyarrhythmia. Journal of Cardiovascular Electrophysiology, 2015, 26, 879-884.	1.7	7
147	Longâ€QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder. Journal of Cardiovascular Electrophysiology, 2015, 26, 1039-1044.	1.7	27
148	Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial. Heart Rhythm, 2015, 12, 2010-2017.	0.7	25
149	Apical vs. non-apical right ventricular pacing in cardiac resynchronization therapy: a meta-analysis. Europace, 2015, 17, 1259-1266.	1.7	41
150	Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. Europace, 2015, 17, 1085.1-1091.	1.7	16
151	Effects of Statins on First and Recurrent Supraventricular Arrhythmias in Patients With Mild Heart Failure (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 497	1.6	6
152	The Effect of ICD Programming on Inappropriate and Appropriate ICD Therapies in Ischemic and Nonischemic Cardiomyopathy: The MADITâ€RIT Trial. Journal of Cardiovascular Electrophysiology, 2015, 26, 424-433.	1.7	31
153	Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction. Circulation: Heart Failure, 2015, 8, 725-732.	3.9	18
154	Safe MRI in Patients With an Upgraded (Conditional) Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2015, 65, 2589-2590.	2.8	4
155	Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT. Europace, 2015, 17, 1816-1822.	1.7	11
156	Defibrillation testing is not required during routine ICD implantation: Figure 1. European Heart Journal, 2015, 36, 2508-2509.	2.2	5
157	Temporal Influence of Heart Failure Hospitalizations Prior to Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy With Defibrillator on Subsequent Outcome in Mild Heart Failure Patients (from MADIT-CRT). American Journal of Cardiology, 2015, 115, 1423-1427.	1.6	5
158	Sex Differences in Longâ€Term Outcomes With Cardiac Resynchronization Therapy in Mild Heart Failure Patients With Left Bundle Branch Block. Journal of the American Heart Association, 2015, 4, .	3.7	37
159	Inverse Relationship of Blood Pressure to Long-Term Outcomes and Benefit of Cardiac Resynchronization Therapy in Patients With Mild Heart Failure. Circulation: Heart Failure, 2015, 8, 921-926.	3.9	10
160	Long-term outcome with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block from US and Europe MADIT-CRT. Heart Failure Reviews, 2015, 20, 535-543.	3.9	4
161	Characterization and predictors of first and subsequent inappropriate ICD therapy by heart rate ranges: Result of the MADIT-RIT efficacy analysis. Heart Rhythm, 2015, 12, 2030-2037.	0.7	10
162	Saving lives with appropriate ICD therapy in elderly patients. Nature Reviews Cardiology, 2015, 12, 504-506.	13.7	0

#	Article	IF	Citations
163	Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients. Circulation, 2015, 132, 1613-1619.	1.6	199
164	Effect of Cardiac Resynchronization Therapy in Patients With Insulin-Treated Diabetes Mellitus. American Journal of Cardiology, 2015, 116, 393-399.	1.6	8
165	The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. European Heart Journal, 2015, 36, 440-448.	2.2	68
166	Abstract 15501: True Bipolar Left Ventricular Pacing is Associated With Better Survival in Cardiac Resynchronization Therapy Patients. Circulation, 2015, 132, .	1.6	1
167	Response to Letter Regarding, â€œPR Interval Identifies Clinical Response in Patients With Non-Left Bundle Branch Block: A Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Sub-Studyâ€•by Kutyifa et al. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1280-1280.	4.8	3
168	Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy withÂpacemaker on mortality in heart failure patients: results of a highâ€volume, singleâ€centre experience. European Journal of Heart Failure, 2014, 16, 1323-1330.	7.1	55
169	Survival with Cardiac-Resynchronization Therapy. New England Journal of Medicine, 2014, 371, 477-478.	27.0	18
170	Comparison of Age (<75ÂYears Versus â‰¥75ÂYears) to Risk of Ventricular Tachyarrhythmias and Implantable Cardioverter Defibrillator Shocks (from the Multicenter Automatic Defibrillator) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 T 114, 1855-1860.	1.6	14
171	Predictors of Spontaneous Reverse Remodeling in Mild Heart Failure Patients With Left Ventricular Dysfunction. Circulation: Heart Failure, 2014, 7, 565-572.	3.9	24
172	Response to Letter Regarding Article, "Syncope in High-Risk Cardiomyopathy Patients With Implantable Defibrillators: Frequency, Risk Factors, Mechanisms, and Association With Mortality: Results From the Multicenter Automatic Defibrillator Implantation Trialâ€“Reduce Inappropriate Therapy (MADIT-RIT) Study". Circulation, 2014, 130, e133.	1.6	0
173	A Metric for Evaluating the Cardiac Response to ResynchronizationÂTherapy. American Journal of Cardiology, 2014, 113, 1371-1377.	1.6	11
174	The Effect of Intermittent Atrial Tachyarrhythmia on Heart Failure or Death inÂCardiac Resynchronization Therapy WithÂDefibrillator Versus Implantable Cardioverter-Defibrillator Patients. Journal of the American College of Cardiology, 2014, 63, 1190-1197.	2.8	28
175	Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure. New England Journal of Medicine, 2014, 370, 1694-1701.	27.0	283
176	Syncope in High-Risk Cardiomyopathy Patients With Implantable Defibrillators: Frequency, Risk Factors, Mechanisms, and Association With Mortality. Circulation, 2014, 129, 545-552.	1.6	45
177	Mortality Reduction in Relation to Implantable Cardioverter Defibrillator Programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circulation: Arrhythmia and Electrophysiology, 2014, 7, 785-792.	4.8	101
178	Association Between Frequency of Atrial and Ventricular Ectopic Beats and Biventricular Pacing Percentage and Outcomes in Patients With Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2014, 64, 971-981.	2.8	50
179	Left Ventricular Ejection Fraction Normalization in Cardiac Resynchronization Therapy and Risk of Ventricular Arrhythmias and Clinical Outcomes. Circulation, 2014, 130, 2278-2286.	1.6	153
180	ICD Programming to Reduce Shocks and Improve Outcomes. Current Cardiology Reports, 2014, 16, 496.	2.9	4

#	Article	IF	Citations
181	Comparison of Low Versus High (>40Âmm Hg) Pulse Pressure to Predict the Benefit of Cardiac Resynchronization Therapy for Heart Failure (from the Multicenter Automatic Defibrillator) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 1053-1058.	1.6	4
182	Cardiac resynchronization therapy is associated with reductions in left atrial volume and inappropriate implantable cardioverter-defibrillator therapy in MADIT-CRT. Heart Rhythm, 2014, 11, 1001-1007.	0.7	4
183	Smoking is associated with an increased risk of first and recurrent ventricular tachyarrhythmias in ischemic and nonischemic patients with mild heart failure: A MADIT-CRT substudy. Heart Rhythm, 2014, 11, 822-827.	0.7	8
184	PR Interval Identifies Clinical Response in Patients With Nonâ€“Left Bundle Branch Block. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 645-651.	4.8	98
185	The Effect of Weight Loss on Clinical Outcomes in Patients Implanted With a Cardiac Resynchronization Therapy Deviceâ€”A MADIT-CRT Substudy. Journal of Cardiac Failure, 2014, 20, 183-189.	1.7	12
186	Clinical Impact, Safety, and Efficacy of Singleâ€•versus Dualâ€€Coil ICD Leads in MADITâ€€CRT. Journal of Cardiovascular Electrophysiology, 2013, 24, 1246-1252.	1.7	36
187	The Influence of Left Ventricular Ejection Fraction on the Effectiveness of Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2013, 61, 936-944.	2.8	86
188	Risk Factors and Outcomes Associated With the Development of Myocardial Ischemic Events in Patients Who Receive Cardiac Resynchronization Therapy. American Journal of Cardiology, 2013, 112, 1896-1900.	1.6	2
189	Impact of Carvedilol and Metoprolol on Inappropriate Implantable Cardioverter-Defibrillator Therapy. Journal of the American College of Cardiology, 2013, 62, 1343-1350.	2.8	39
190	Dyssynchrony and the Risk of Ventricular Arrhythmias. JACC: Cardiovascular Imaging, 2013, 6, 432-444.	5.3	72
191	Effect on Cardiac Function of Cardiac Resynchronization Therapy in Patients With Right Bundle Branch Block (from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	2.8	65
192	Effects of cardiac resynchronization therapy on left ventricular mass and wall thickness in mild heart failure patients in MADIT-CRT. Heart Rhythm, 2013, 10, 354-360.	0.7	7
193	Impact of the right ventricular lead position on clinical outcome and on the incidence of ventricular tachyarrhythmias in patients with CRT-D. Heart Rhythm, 2013, 10, 1770-1777.	0.7	39
194	Atrioventricular delay programming and the benefit of cardiac resynchronization therapy in MADIT-CRT. Heart Rhythm, 2013, 10, 1136-1143.	0.7	25
195	Clinical significance of ventricular tachyarrhythmias in patients treated with CRT-D. Heart Rhythm, 2013, 10, 943-950.	0.7	4
196	Ambulatory ECG Monitoring in Atrial Fibrillation Management. Progress in Cardiovascular Diseases, 2013, 56, 143-152.	3.1	41
197	Left ventricular lead location and the risk of ventricular arrhythmias in the MADIT-CRT trial. European Heart Journal, 2013, 34, 184-190.	2.2	42
198	How to Assess the Nonresponder to Cardiac Resynchronization Therapyâ€“A Comprehensive Stepwise Approach. Revista Espanola De Cardiologia (English Ed), 2012, 65, 504-510.	0.6	4

#	Article	IF	Citations
199	EvaluaciÃ³n del paciente que no responde al tratamiento de resincronizaciÃ³n cardiaca: un enfoque escalonado completo. Revista Espanola De Cardiologia, 2012, 65, 504-510.	1.2	15
200	Tracing the European course of cardiac resynchronization therapy from 2006 to 2008. Europace, 2010, 12, 692-701.	1.7	39
201	Minimal invasive coronary sinus lead reposition technique for the treatment of phrenic nerve stimulation. Europace, 2008, 10, 1157-1160.	1.7	17
202	Stabilization of the Coronary Sinus Electrode Position with Coronary Stent Implantation to Prevent and Treat Dislocation. Journal of Cardiovascular Electrophysiology, 2007, 18, 303-307.	1.7	45
203	The cardiac arrest centre for the treatment of sudden cardiac arrest due to presumed cardiac cause: aims, function, and structure: position paper of the ACVC association of the ESC, EAPCI, EHRA, ERC, EUSEM, and ESICM. European Heart Journal: Acute Cardiovascular Care, 0, , .	1.0	9